Nyxoah (NASDAQ:NYXH – Get Free Report) and Orchestra BioMed (NASDAQ:OBIO – Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, profitability, risk, institutional ownership, dividends, valuation and earnings.
Valuation and Earnings
This table compares Nyxoah and Orchestra BioMed’s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Nyxoah | $4.70 million | N/A | -$46.77 million | ($1.64) | -6.27 |
| Orchestra BioMed | $2.76 million | 68.73 | -$49.12 million | ($1.48) | -3.58 |
Nyxoah has higher revenue and earnings than Orchestra BioMed. Nyxoah is trading at a lower price-to-earnings ratio than Orchestra BioMed, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Insider & Institutional Ownership
53.6% of Orchestra BioMed shares are owned by institutional investors. 6.7% of Orchestra BioMed shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Analyst Recommendations
This is a breakdown of current ratings and price targets for Nyxoah and Orchestra BioMed, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nyxoah | 0 | 1 | 5 | 0 | 2.83 |
| Orchestra BioMed | 0 | 0 | 2 | 0 | 3.00 |
Nyxoah presently has a consensus target price of $20.20, suggesting a potential upside of 96.31%. Orchestra BioMed has a consensus target price of $17.00, suggesting a potential upside of 220.75%. Given Orchestra BioMed’s stronger consensus rating and higher probable upside, analysts clearly believe Orchestra BioMed is more favorable than Nyxoah.
Profitability
This table compares Nyxoah and Orchestra BioMed’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nyxoah | -843.49% | -42.14% | -33.55% |
| Orchestra BioMed | -2,330.46% | -70.18% | -49.17% |
Summary
Nyxoah beats Orchestra BioMed on 7 of the 13 factors compared between the two stocks.
About Nyxoah
Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
About Orchestra BioMed
Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.
Receive News & Ratings for Nyxoah Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nyxoah and related companies with MarketBeat.com's FREE daily email newsletter.
